Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants
Emergence of highly transmissible SARS-CoV-2 variants of concern that are resistant to current therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies.
Gene Editing for ALPK1 p.Thr237Met
ROSAH syndrome is a rare genetic disease caused by a mutation in the human alpha kinase 1 (ALPK1) gene (p.Thr237Met), leading to vision loss, swollen optic nerves, dry mouth, enlarged spleen, and frequent headaches. Researchers in the Laboratory of Clinical Immunology and Microbiology (LCIM) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach that can precisely fix the ALPK1 mutation without causing unwanted changes in the patient’s DNA.
Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules
Muramyl Dipeptide as a Therapeutic Agent for Inflammation
LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders
Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites
Malaria is one of the worlds deadliest infectious diseases, causing an estimated 249 million cases and 608,000 deaths annually, with children in the regions of Africa and South Asia being most vulnerable. Approx 2,000 cases of malaria are reported in the United States each year, by travelers from malaria-risk countries. Malaria is a mosquito-borne parasitic disease transmitted through the bite of infected female mosquitoes, which introduces Plasmodium sporozoites into the bloodstream of the human host.
Neutralizing Antibodies Against West Nile Virus
West Nile virus (WNV) is a mosquito-borne virus that can cause severe disease affecting the brain and nervous system, especially in older adults and people with weakened immune systems. There is no approved human vaccine or specific antiviral treatment for WNV.
Nanobodies Neutralizing Lassa Virus
Summary:
Researchers at the National Cancer Institute (NCI) seek parties interested in collaborative research and/or licensing to further develop neutralizing nanobodies targeting Lassa virus.
Neutralizing Monoclonal Antibodies Against West Nile Virus
West Nile virus (WNV) is a mosquito-borne flavivirus that can cause fever and, in some cases, severe neurologic disease. There is no approved human vaccine or specific antiviral treatment for WNV.